vs

Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and Momentus Inc. (MNTS). Click either name above to swap in a different company.

Astria Therapeutics, Inc. is the larger business by last-quarter revenue ($706.0K vs $363.0K, roughly 1.9× Momentus Inc.).

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.

Momentus Inc, sometimes styled Momentus space, is an American spaceflight company founded by Mikhail Kokorich in 2017. The company is focused on offering space infrastructure services in the form of on-orbit services. The company advertises three orbital tug services which are based around spacecraft electric propulsion and vary in payload mass and Delta-v. As of late 2022 the company has launched one demonstration mission, which produced mixed results.

ATXS vs MNTS — Head-to-Head

Bigger by revenue
ATXS
ATXS
1.9× larger
ATXS
$706.0K
$363.0K
MNTS

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ATXS
ATXS
MNTS
MNTS
Revenue
$706.0K
$363.0K
Net Profit
$-31.6M
Gross Margin
100.0%
Operating Margin
-4830.6%
-2446.3%
Net Margin
-4482.0%
Revenue YoY
27.4%
Net Profit YoY
-29.0%
EPS (diluted)
$-0.55
$-45.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATXS
ATXS
MNTS
MNTS
Q4 25
$363.0K
Q3 25
$706.0K
$234.0K
Q2 25
$191.0K
Q1 25
$322.0K
Q4 24
$285.0K
Q3 24
$0
$107.0K
Q2 24
$1.2M
Q1 24
$513.0K
Net Profit
ATXS
ATXS
MNTS
MNTS
Q4 25
Q3 25
$-31.6M
$-11.1M
Q2 25
$-6.5M
Q1 25
$-6.2M
Q4 24
Q3 24
$-24.5M
$-7.8M
Q2 24
$-7.0M
Q1 24
$-8.3M
Gross Margin
ATXS
ATXS
MNTS
MNTS
Q4 25
100.0%
Q3 25
100.0%
Q2 25
99.0%
Q1 25
100.0%
Q4 24
100.0%
Q3 24
38.3%
Q2 24
100.0%
Q1 24
100.0%
Operating Margin
ATXS
ATXS
MNTS
MNTS
Q4 25
-2446.3%
Q3 25
-4830.6%
-2669.2%
Q2 25
-3112.0%
Q1 25
-1920.8%
Q4 24
-2385.6%
Q3 24
-7096.3%
Q2 24
-576.0%
Q1 24
-1623.2%
Net Margin
ATXS
ATXS
MNTS
MNTS
Q4 25
Q3 25
-4482.0%
-4732.5%
Q2 25
-3377.0%
Q1 25
-1916.8%
Q4 24
Q3 24
-7250.5%
Q2 24
-580.3%
Q1 24
-1620.5%
EPS (diluted)
ATXS
ATXS
MNTS
MNTS
Q4 25
$-45.15
Q3 25
$-0.55
$-1.08
Q2 25
$-1.23
Q1 25
$-1.64
Q4 24
$-392.58
Q3 24
$-0.42
$-6.26
Q2 24
$-5.92
Q1 24
$-9.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATXS
ATXS
MNTS
MNTS
Cash + ST InvestmentsLiquidity on hand
$227.7M
$12.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$233.3M
$17.1M
Total Assets
$271.9M
$40.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATXS
ATXS
MNTS
MNTS
Q4 25
$12.8M
Q3 25
$227.7M
$670.0K
Q2 25
$132.0K
Q1 25
$3.4M
Q4 24
$1.6M
Q3 24
$344.3M
$798.0K
Q2 24
$897.0K
Q1 24
$1.7M
Stockholders' Equity
ATXS
ATXS
MNTS
MNTS
Q4 25
$17.1M
Q3 25
$233.3M
$-694.0K
Q2 25
$-10.0M
Q1 25
$-6.0M
Q4 24
$-7.8M
Q3 24
$341.7M
$-5.4M
Q2 24
$-1.8M
Q1 24
$3.5M
Total Assets
ATXS
ATXS
MNTS
MNTS
Q4 25
$40.3M
Q3 25
$271.9M
$19.6M
Q2 25
$9.2M
Q1 25
$11.7M
Q4 24
$10.0M
Q3 24
$361.6M
$14.1M
Q2 24
$15.0M
Q1 24
$18.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATXS
ATXS
MNTS
MNTS
Operating Cash FlowLast quarter
$-32.3M
$-10.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATXS
ATXS
MNTS
MNTS
Q4 25
$-10.5M
Q3 25
$-32.3M
$-5.3M
Q2 25
$-3.2M
Q1 25
$-4.2M
Q4 24
$-5.7M
Q3 24
$-28.0M
$-4.5M
Q2 24
$-1.1M
Q1 24
$-5.3M
Free Cash Flow
ATXS
ATXS
MNTS
MNTS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$-28.0M
Q2 24
Q1 24
Capex Intensity
ATXS
ATXS
MNTS
MNTS
Q4 25
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons